The ITC's Potential Role In Hatch-Waxman Litigation

Law360, New York (April 19, 2017, 12:21 PM EDT) -- Imagine a scenario where a branded pharmaceutical company holds U.S. patents claiming a process for making an active pharmaceutical ingredient, intermediates of the API, or the finished branded drug product. The process patents were not listed in the U.S. Food and Drug Administration’s Orange Book. The branded pharmaceutical company did not prevail in the abbreviated new drug application litigation over the patents that were listed in the Orange Book. The generic challenger together with foreign manufacturers have plans for the sale of imported batches of the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.